Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Average (2016 - 2025)

Historic Equity Average for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to $509.1 million.

  • Viridian Therapeutics, Inc.\DE's Equity Average fell 1768.18% to $509.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $509.1 million, marking a year-over-year decrease of 1768.18%. This contributed to the annual value of $556.8 million for FY2024, which is 3304.02% up from last year.
  • Viridian Therapeutics, Inc.\DE's Equity Average amounted to $509.1 million in Q3 2025, which was down 1768.18% from $559.8 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Equity Average's 5-year high stood at $689.6 million during Q4 2024, with a 5-year trough of $102.5 million in Q2 2021.
  • Moreover, its 5-year median value for Equity Average was $362.8 million (2023), whereas its average is $369.7 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 61897.99% in 2021, then crashed by 1768.18% in 2025.
  • Viridian Therapeutics, Inc.\DE's Equity Average (Quarter) stood at $196.2 million in 2021, then surged by 104.96% to $402.0 million in 2022, then fell by 9.76% to $362.8 million in 2023, then soared by 90.07% to $689.6 million in 2024, then fell by 26.18% to $509.1 million in 2025.
  • Its Equity Average stands at $509.1 million for Q3 2025, versus $559.8 million for Q2 2025 and $638.1 million for Q1 2025.